Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186407 · ClinicalTrials.gov registry record · Phase 2
Autologous Stem Cell Rescue for Primary Amyloidosis
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00186407: Completed Phase 2 study, sponsored by Stanford University.
NCT00186407 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186407, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
To evaluate the role of high dose therapy and autologous hematopoietic cell transplant for amyloidosis.
Interventions
- PROCEDURE high dose chemo then auto hematopoietic cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 1998-04 |
| Est. Completion | 2010-02 |
| Phase | Phase 2 |
What the finished NCT00186407 record still lists
NCT00186407 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 1 intervention - of which high dose chemo then auto hematopoietic cell transplant is the first listed.
NCT00186407 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00186407 about?
NCT00186407 is a clinical study titled "Autologous Stem Cell Rescue for Primary Amyloidosis". To evaluate the role of high dose therapy and autologous hematopoietic cell transplant for amyloidosis.
What is the current status of trial NCT00186407?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 1998-04. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00186407?
The interventions under investigation include: high dose chemo then auto hematopoietic cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00186407?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00186407's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia